Application of Microsponge Drug Platform to Enhance Methotrexate Administration in Rheumatoid Arthritis Therapy

Area of Science:

• Nanotechnology
• Materials Science
• Pharmacology

Background:

• Rheumatoid arthritis (RA) is a chronic autoimmune disease causing joint inflammation and damage.
• Conventional methotrexate (MTX) therapy for RA is limited by adverse effects and lack of release control.

Purpose of the Study:

• To develop a novel nanotechnological slow-release drug delivery platform using hyaluronic acid Microsponge (MSP).
• To enable subcutaneous administration of MTX for improved rheumatoid arthritis (RA) treatment.

Main Methods:

• Hyaluronic acid Microsponge (MSP) was synthesized as a freeze-dried powder for enhanced stability and precise dosing.
• MTX loading efficiency and release kinetics were evaluated.
• A preclinical rat model of RA was used to assess therapeutic efficacy and safety.

Main Results:

• The developed MSP exhibited high MTX loading efficiency and a sustained release profile over one month, with minimal initial burst release.
• MTX-loaded MSP demonstrated nearly double the therapeutic efficacy compared to conventional MTX in a preclinical RA model.
• The study confirmed the improved performance and safety profile of the MSP platform through replicated preclinical studies.

Conclusions:

• The MSP drug delivery platform shows significant potential for clinical application in RA therapy.
• Sustained slow release of MTX via MSP enhances therapeutic outcomes and minimizes side effects.
• This nanotechnological approach offers a promising strategy for improving the management of rheumatoid arthritis.